|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MEDAG |
Gene summary for MEDAG |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MEDAG | Gene ID | 84935 |
| Gene name | mesenteric estrogen dependent adipogenesis | |
| Gene Alias | AWMS3 | |
| Cytomap | 13q12.3 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q5VYS4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84935 | MEDAG | C51 | Human | Oral cavity | OSCC | 2.24e-06 | 5.09e-01 | 0.2674 |
| 84935 | MEDAG | NEOLP-1 | Human | Oral cavity | NEOLP | 1.91e-05 | 4.19e-01 | -0.0194 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00454448 | Oral cavity | OSCC | fat cell differentiation | 120/7305 | 229/18723 | 2.48e-05 | 2.32e-04 | 120 |
| GO:00455983 | Oral cavity | OSCC | regulation of fat cell differentiation | 77/7305 | 139/18723 | 6.36e-05 | 5.18e-04 | 77 |
| GO:00456006 | Oral cavity | OSCC | positive regulation of fat cell differentiation | 41/7305 | 66/18723 | 1.20e-04 | 8.60e-04 | 41 |
| GO:004560022 | Oral cavity | NEOLP | positive regulation of fat cell differentiation | 24/2005 | 66/18723 | 3.20e-08 | 1.35e-06 | 24 |
| GO:004559821 | Oral cavity | NEOLP | regulation of fat cell differentiation | 37/2005 | 139/18723 | 1.12e-07 | 4.05e-06 | 37 |
| GO:004544422 | Oral cavity | NEOLP | fat cell differentiation | 50/2005 | 229/18723 | 6.79e-07 | 1.93e-05 | 50 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MEDAG | SNV | Missense_Mutation | c.466N>G | p.Ile156Val | p.I156V | Q5VYS4 | protein_coding | deleterious(0.01) | probably_damaging(0.968) | TCGA-A8-A07P-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD | |
| MEDAG | SNV | Missense_Mutation | novel | c.615N>A | p.Phe205Leu | p.F205L | Q5VYS4 | protein_coding | tolerated(0.23) | probably_damaging(0.969) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MEDAG | insertion | In_Frame_Ins | novel | c.363_364insTTT | p.Val121_Gln122insPhe | p.V121_Q122insF | Q5VYS4 | protein_coding | TCGA-AO-A03R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
| MEDAG | insertion | Nonsense_Mutation | novel | c.364_365insCTCAACTATAAAGTGGGAATAGTAATAATACCATTA | p.Gln122delinsProGlnLeuTerSerGlyAsnSerAsnAsnThrIleLys | p.Q122delinsPQL*SGNSNNTIK | Q5VYS4 | protein_coding | TCGA-AO-A03R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
| MEDAG | SNV | Missense_Mutation | c.525G>T | p.Lys175Asn | p.K175N | Q5VYS4 | protein_coding | deleterious(0.03) | benign(0.095) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| MEDAG | SNV | Missense_Mutation | c.320N>T | p.Arg107Met | p.R107M | Q5VYS4 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-NH-A6GA-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | PD | |
| MEDAG | SNV | Missense_Mutation | novel | c.891G>T | p.Glu297Asp | p.E297D | Q5VYS4 | protein_coding | deleterious_low_confidence(0.02) | benign(0.416) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| MEDAG | SNV | Missense_Mutation | novel | c.847C>A | p.Leu283Ile | p.L283I | Q5VYS4 | protein_coding | tolerated_low_confidence(0.12) | possibly_damaging(0.724) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MEDAG | SNV | Missense_Mutation | rs764239466 | c.493N>T | p.Arg165Trp | p.R165W | Q5VYS4 | protein_coding | deleterious(0.04) | benign(0.007) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MEDAG | SNV | Missense_Mutation | novel | c.464N>C | p.Val155Ala | p.V155A | Q5VYS4 | protein_coding | tolerated(0.36) | benign(0.083) | TCGA-AX-A3G8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |